Avitide Secures Series C Financing

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    16 Cavendish Court Lebanon, NH 03766 USA
  • Company Description
    Avitide develops customized biopharmaceutical affinity purification products. The Avitide platform reduces bioprocess development timelines, program risk, and cost of manufacture by providing turnkey, cost-effective, highly specific affinity purification solutions.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series C
  • Proceeds Purposes
    The proceeds will accelerate commercialization of Avitide’s on-demand affinity purification platform, with a focus on biopharmaceutical drug products that include an array of molecules such as proteins, enzymes, antibody-based therapeutics, recombinant vaccines, gene therapies and biosimilars. The financing is expected to take the company to profitability within the next two years.
  • M&A Terms
  • Venture Investor
    NeoMed Management
  • Venture Investor
    Polaris Partners
  • Venture Investor
    Borealis Ventures
  • Venture Investor
    SV Life Sciences
  • Venture Investor

Trending on Xconomy